Alaunos Therapeutics Reports Q3 2025 Financial Results with $1.16 Million Net Loss

Alaunos Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $1.16 million for the three months ending September 30, compared to a loss of $1.13 million in the same period last year. For the nine months ended September 30, 2025, the company recorded a net loss of $3.28 million, a decrease from the $3.94 million loss reported for the same period in 2024. The company did not generate any revenue during the third quarter, maintaining a total revenue of $2,000 for the nine months, down from $6,000 in the previous year. The basic and diluted loss per share for the third quarter was $0.55, compared to $0.70 in the prior year.

Alaunos' operating expenses for the third quarter totaled $1.19 million, slightly higher than the $1.15 million reported in the same quarter of 2024. Research and development expenses increased significantly to $469,000 from $143,000 year-over-year, primarily due to higher stock-based compensation and consulting fees related to the company's obesity program. Conversely, general and administrative expenses decreased to $718,000 from $1.01 million, attributed to reduced salary expenses and operational costs following workforce reductions and strategic reprioritization.

The company’s balance sheet as of September 30, 2025, showed total assets of $3.72 million, up from $2.76 million at the end of 2024. Cash and cash equivalents increased to $1.94 million from $1.09 million, while total liabilities rose to $921,000 from $692,000. Stockholders' equity also improved to $2.80 million, compared to $2.06 million at the end of the previous fiscal year. The increase in cash was bolstered by financing activities, including the issuance of common stock and preferred stock, which generated approximately $3.26 million in net cash flows.

Strategically, Alaunos has shifted its focus from oncology to developing oral small molecules for obesity and metabolic disorders. The company has engaged a contract development and manufacturing organization to synthesize active pharmaceutical ingredients for its product candidates and has initiated preclinical studies. However, the company has also faced challenges, including the termination of its exclusive license agreement with Precigen and the wind-down of its TCR-T Library Phase 1/2 Trial due to high development costs and a challenging financing environment.

Looking ahead, Alaunos anticipates that its cash resources will be sufficient to fund operations into the first quarter of 2026. However, the company has expressed substantial doubt regarding its ability to continue as a going concern beyond this period without securing additional financing. The company is actively exploring strategic alternatives, including potential mergers, acquisitions, or partnerships, to enhance its financial position and operational capabilities.